Imatinibe mesilato no Brasil Imatinibe mesylate in Brazil

Other literature type, Article English OPEN
Lima, Marcos;
(2005)
  • References (5)

    1. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.

    2. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-475.

    3. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104: 2.204-2.205.

    4. Cortes J, Faderl S, Estey E et al. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 2005;23: 2.805-2.812.

    5. Funke VAM et al. Therapy of chronic myeloid leukemia with imatinib mesylate in brazil: A study of 98 cases. Rev bras hematol hemoter 2005; 27(3):159-165.

  • Metrics
Share - Bookmark